98%
921
2 minutes
20
Image enhancement methods have been widely studied to improve the visual quality of diverse images, implicitly assuming that all human observers have normal vision. However, a large population around the world suffers from Color Vision Deficiency (CVD). Enhancing images to compensate for their perceptions remains a challenging issue. Existing CVD compensation methods have two drawbacks: first, the available datasets and validations have not been rigorously tested by CVD individuals; second, these methods struggle to strike an optimal balance between contrast enhancement and naturalness preservation, which often results in suboptimal outcomes for individuals with CVD. To address these issues, we develop the first large-scale, CVD-individual-labeled dataset called FZU-CVDSet and a CVD-friendly recoloring algorithm called ColorAssist. In particular, we design a perception-guided feature extraction module and a perception-guided diffusion transformer module that jointly achieve efficient image recoloring for individuals with CVD. Comprehensive experiments on both FZU-CVDSet and subjective tests in hospitals demonstrate that the proposed ColorAssist closely aligns with the visual perceptions of individuals with CVD, achieving superior performance compared with the state-of-the-arts. The source code will be made publicly available after the peer review process.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/TIP.2025.3602643 | DOI Listing |
Rev Cardiovasc Med
August 2025
Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, 100029 Beijing, China.
Background: The incidence of unstable angina (UA), a type of cardiovascular disease (CVD), has increased in recent years. Meanwhile, timely percutaneous coronary intervention (PCI) or percutaneous transluminal coronary angioplasty (PTCA) procedures are crucial for patients with UA who also have diabetes mellitus (DM). Additionally, exploring other factors that may influence the prognosis of these patients could provide long-term benefits.
View Article and Find Full Text PDFRen Fail
December 2025
Department of Nephrology, Kidney Disease Medical Center, Tianjin Medical University General Hospital, National Key Clinical Specialty, Tianjin Key Medical Discipline, Tianjin, China.
Purpose: This study aimed to investigate the association between body roundness index (BRI) and deaths from all causes and cardiovascular disease (CVD) in participants with chronic kidney disease (CKD).
Materials And Methods: The data was sourced from the National Health and Nutrition Examination Survey (NHANES) 1999-2018. Cox proportional hazards regression along with restricted cubic splines were applied to assess the associations of BRI with deaths from all causes and CVD in individuals with CKD.
Ren Fail
December 2025
Renal Division, Department of Medicine, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China.
The Grams model, designed to predict adverse event risks in advanced chronic kidney disease (CKD) patients, was evaluated in a Chinese cohort of 1,333 patients with eGFR below 30 mL/min/1.73 m. The model demonstrated moderate to good discrimination across outcomes, performing well in predicting kidney replacement therapy (KRT) but overestimating the risks of cardiovascular disease (CVD) and mortality.
View Article and Find Full Text PDFCurr Atheroscler Rep
September 2025
Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, 521 19th Street South-GSB 444, Birmingham, AL, 35233, USA.
Purpose Of Review: This review examines cardiovascular disease (CVD) risk prediction models relevant to older adults, a rapidly expanding population with elevated CVD risk. It discusses model characteristics, performance metrics, and clinical implications.
Recent Findings: Some models have been developed specifically for older adults, while several others consider a broader age range, including some older individuals.
Radiology
September 2025
Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Plc, Box 1234, New York, NY 10029.
Background The prognostic value of baseline visual emphysema scoring at low-dose CT (LDCT) in lung cancer screening cohorts is unknown. Purpose To determine whether a single visual emphysema score at LDCT is predictive of 25-year mortality from all causes, chronic obstructive pulmonary disease (COPD), and cardiovascular disease (CVD). Materials and Methods In this prospective cohort study, asymptomatic adults aged 40-85 years with a history of smoking underwent baseline LDCT screening for lung cancer between June 2000 and December 2008.
View Article and Find Full Text PDF